Sign in
4

Changes in Ownership

Contineum Therapeutics, Inc. Filed Acc 0001628280-26-046654

CMO & Head of Development sold 10,833 shares at $16.02 ($173,590)

  • CMO & Head of Development acquired 10,833 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Watkins Tim CMO & Head of Development 2026-06-30 Option exercise 10b5-1 +10,833 $4.50 $48,749 19,794 D: show line 1 in the form
Watkins Tim CMO & Head of Development 2026-06-30 Sale 10b5-1 −10,833 $16.02 $173,590 8,961 D: show line 2 in the form
Open-market sales · 10,833 sh · avg $16.02 · $173,590

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Watkins Tim CMO & Head of Development 2026-06-30 Option exercise · Stock Option (right to buy) 10b5-1 −10,833 238,334 D: show line 3 in the form
Loading xslF345X06/wk-form4_1782947093.xml…